High Insider Owned Growth Stocks With Earnings Up To 69%

In the midst of geopolitical tensions and shifting consumer spending patterns, global markets have experienced a volatile week, with major U.S. indexes seeing early gains erased by sharp losses later on. As investors navigate these uncertainties, growth companies with high insider ownership can be particularly appealing due to their potential alignment of interests between company insiders and shareholders, which may provide an added layer of confidence in turbulent times.

Top 10 Growth Companies With High Insider Ownership

Name	Insider Ownership	Earnings Growth
Archean Chemical Industries (NSEI:ACI)	22.9%	50.1%
Seojin SystemLtd (KOSDAQ:A178320)	32.1%	39.9%
Clinuvel Pharmaceuticals (ASX:CUV)	10.4%	26.2%
SKS Technologies Group (ASX:SKS)	29.7%	24.8%
Pricol (NSEI:PRICOLLTD)	25.4%	25.2%
Laopu Gold (SEHK:6181)	36.4%	43.2%
Plenti Group (ASX:PLT)	12.7%	120.1%
HANA Micron (KOSDAQ:A067310)	18.3%	119.4%
Fulin Precision (SZSE:300432)	13.6%	71%
Findi (ASX:FND)	35.8%	133.7%

Click here to see the full list of 1450 stocks from our Fast Growing Companies With High Insider Ownership screener.

Underneath we present a selection of stocks filtered out by our screen.

BioArctic (OM:BIOA B)

Simply Wall St Growth Rating: ★★★★★★

Overview: BioArctic AB (publ) is a Swedish company focused on developing biological drugs for central nervous system disorders, with a market cap of SEK21.66 billion.

Operations: BioArctic generates its revenue primarily from the biotechnology segment, totaling SEK257.35 million.

Insider Ownership: 33.8%

Earnings Growth Forecast: 38.5% p.a.

BioArctic's recent collaboration with Bristol Myers Squibb, involving a US$100 million upfront payment and potential milestones up to US$1.25 billion, highlights its growth potential. Despite volatile share prices, BioArctic is expected to achieve high revenue growth of 32.1% annually, surpassing market averages. The company is forecasted to become profitable within three years with a strong return on equity projected at 37.5%. While insider transactions have not been substantial recently, the stock trades significantly below estimated fair value.

• Navigate through the intricacies of BioArctic with our comprehensive analyst estimates report here.
• The valuation report we've compiled suggests that BioArctic's current price could be quite moderate.

Angelalign Technology (SEHK:6699)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Angelalign Technology Inc. is an investment holding company that focuses on researching, developing, designing, manufacturing, and marketing clear aligner treatment solutions in the People's Republic of China with a market cap of approximately HK$10.84 billion.

Operations: The company generates revenue primarily from its Dental Equipment & Supplies segment, totaling CN¥1.72 billion.

Insider Ownership: 17.6%

Earnings Growth Forecast: 69.6% p.a.

Angelalign Technology is poised for significant earnings growth, forecasted at 69.6% annually, outpacing the Hong Kong market. Despite a current profit margin decline to 2.5%, the company trades at 13.2% below its estimated fair value with analysts predicting a stock price increase of 28%. Revenue growth is projected at 14.5% per year, exceeding market averages but not reaching high-growth benchmarks. Recent address changes indicate ongoing operational adjustments without impacting insider trading activities.

• Dive into the specifics of Angelalign Technology here with our thorough growth forecast report.
• In light of our recent valuation report, it seems possible that Angelalign Technology is trading beyond its estimated value.

APT Medical (SHSE:688617)

Simply Wall St Growth Rating: ★★★★★★

Overview: APT Medical Inc. focuses on the research, development, manufacturing, and supply of electrophysiology and vascular interventional medical devices in China, with a market cap of CN¥36.74 billion.

Operations: The company generates its revenue primarily from medical products, amounting to CN¥1.96 billion.

Insider Ownership: 22.1%

Earnings Growth Forecast: 28.8% p.a.

APT Medical's recent earnings report shows strong growth, with sales reaching CNY 2.07 billion and net income increasing to CNY 673.48 million. Earnings per share rose to CNY 6.96, reflecting robust financial health. The company's revenue is forecasted to grow at a substantial rate of 29.1% annually, outpacing the Chinese market average of 13.4%. Despite no significant insider trading activity recently, high insider ownership aligns interests with shareholders and supports its growth trajectory.

• Unlock comprehensive insights into our analysis of APT Medical stock in this growth report.
• Our comprehensive valuation report raises the possibility that APT Medical is priced higher than what may be justified by its financials.

Next Steps

• Take a closer look at our Fast Growing Companies With High Insider Ownership list of 1450 companies by clicking here.
• Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.
• Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.

Want To Explore Some Alternatives?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com